Developmental neurobiologists at St. Jude have used a 3D genome to improve understanding of gene regulation during development and disease. Pictured here, left to right, are Victoria Honnell.; Jackie Norrie, Ph.D.; and Marybeth Lupo, Ph.D., who work in the lab of Michael Dyer, Ph.D.
Like pirates on a treasure hunt, St. Jude Children’s Research Hospital scientists have created the first 3D map of a mouse genome and used it to discover scientific gold. The gold includes insight from machine learning into genomic organization and function during development. The research appears today in the journal Neuron.
“Understanding the way cells organize their genomes during development will help us to understand their ability to respond to stress, injury and disease,” said Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and Howard Hughes Medical Institute investigator. He and Xiang Chen, Ph.D., assistant member of the St. Jude Department of Computational Biology, are the corresponding authors.
The research focused on light-sensing rod cells in the mouse retina. More than 8,000 genes are turned on or off during retinal development. Thousands of regulatory regions across the genome also play a role. Researchers used technology called ultra-deep chromosome conformation capture or Hi-C analysis to map those interactions in mouse rod cells. Previously, 3D genomics has focused primarily on understanding regulation of specific genes and worked with cells growing in the laboratory.
Using integrated analysis of data from a variety of sources and machine learning, investigators showed genomic organization changed in surprising ways at different stages of development. “These changes are not random, but part of the developmental program of cells,” Dyer said.
Dyer and his colleagues have used the same approach to create a 3D genomic map of the mouse cerebellum, a brain structure where medulloblastoma can develop. Medulloblastoma is the most common malignant pediatric brain tumor.
Packaging
The human genome is encoded in the 3 billion chemical bases of human DNA. Since the first human genome was completely sequenced in 2003, researchers have used the technology to identify and study inherited or acquired genomic alterations that lead to cancer and other diseases.
Stretched its entire length, DNA from a single human cell measures about 6 feet long. To function, the DNA is packaged into a microscopic bundle that fits into the nucleus of cells. The resulting DNA loops can bring together otherwise distant regions of the genome. Key details, including a 3D map of loops and the interactions they fostered, were largely a mystery.
3D genome
The current study captured long-distance interactions between promoters (DNA regions that promote gene expression) and enhancers (regions that increase gene expression) at different stages of retinal development. Researchers also tracked changes in genome organization during development. That included the first use of machine learning to gauge how easily accessible genes are for transcription. Chen led the machine-learning effort.
Additional highlights
The research also included the first report of a powerful regulator of gene expression, a super enhancer, that worked in a specific cell at a specific stage of development. The finding is important because super enhancers can be hijacked in developmental cancers of the brain and other organs.
In this study, the scientists determined that when a core regulatory circuit super-enhancer for the Vsx2 gene was deleted, an entire class of neurons (bipolar neurons) was eliminated. No other defects were identified. Deletion of the Vsx2 gene causes many more defects in retinal development so the super-enhancer is highly specific to bipolar neurons.
Researchers developed a genetic mouse model of the defect that scientists are using to study neural circuits in the retina.
Study data and an instructional video are available to researchers worldwide through St. Jude Cloud, an online, cloud-based data-sharing resource.
The first authors are Jackie Norrie, Marybeth Lupo, Beisi Xu, Marc Valentine and Daniel Putnam of St. Jude; and Issam Al Diri, formerly of St. Jude. The other authors are Lyra Griffiths, Jiakun Zhang, John Easton, Ying Shao, Victoria Honnell, Sharon Frase, Shondra Miller and Valerie Stewart of St. Jude; and Dianna Johnson of the University of Tennessee Health Science Center.
The research was supported in part by grants (CA21765, EY014867, EY018599, CA168875) from the National Institutes of Health;Alex’s Lemonade Stand Foundation for Childhood Cancer; the Tully Family Foundation; the Peterson Foundation; HHMI; and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.